公开(公告)号：US20040253218A1

公开(公告)日：2004-12-16

申请号：US10810653

申请日：2004-03-29

Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

Inventor： Michal Eisenbach-Schwartz ,  Ester Yoles ,  Ehud Hauben ,  Irun R. Cohen ,  Pierre Beserman ,  Alon Monsonego ,  Gila Moalem

IPC: A61K045/00 ,  A61K038/17

CPC classification number: A61K38/1709 ,  A61K39/00 ,  A61K39/0007 ,  A61K48/00 ,  A61K2039/5158 ,  C07K14/47 ,  C07K14/705

Abstract: Compositions and methods to promote nerve regeneration or to confer neuroprotection and prevent or inhibit neuronal degeneration within the nervous system, either the central nervous system or the peripheral nervous system, are provided. Treatment involves administering NS-specific activated T cells, or an NS-specific antigen or analog thereof, a peptide derived therefrom or an analog or derivative of said peptide, or a nucleotide sequence encoding said antigen or peptide, or any combination thereof.

公开(公告)号：US20020197270A1

公开(公告)日：2002-12-26

申请号：US10032482

申请日：2002-01-02

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irun R. Cohen ,  Varda Rotter ,  Roland Wolkowicz ,  Pedro Ruiz ,  Neta Erez-Alon ,  Johannes Herkel

IPC: A61K048/00 ,  A61K039/00

CPC classification number: C07K16/30 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/51 ,  C07K16/18 ,  C07K2317/565 ,  C07K2317/73

Abstract: The invention relates to the use of an immunogen selected from the group consisting of (i) an anti-p53 mAb; (ii) a fragment of an anti-p53 mAb; (iii) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (iv) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle, for the preparation of a pharmaceutical composition useful for induction of anti-tumor immunity in mammals, for activating an enhanced immune response to a p53 molecule in mammals, and/or for induction of immune responses to mutated and wild-type forms of a p53 in mammals. The use of anti-p53 mAbs and novel peptides based on the CDR2 and CDR3 of the heavy chains and CDR3 of the light chains of different anti-p53 mAbs are disclosed.

Abstract translation: 本发明涉及选自以下的免疫原的用途：（i）抗p53 mAb; （ii）抗p53 mAb的片段; （iii）基于抗p53 mAb的重链或轻链的CDR的肽，该肽能够引发针对p53的抗体; 和（iv）编码合适的基因递送载体中抗p53mAb的可变（V）区的DNA分子，用于制备用于诱导哺乳动物抗肿瘤免疫的药物组合物，用于激活增强的 对哺乳动物中p53分子的免疫应答，和/或用于诱导哺乳动物中突变​​和野生型形式的p53的免疫应答。 公开了使用抗p53 mAb和基于不同抗p53 mAb的轻链的CDR2和CDR3的CDR3和新型肽。

公开(公告)号：US20030190323A1

公开(公告)日：2003-10-09

申请号：US10307326

申请日：2002-12-02

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Irun R. Cohen ,  Dana Elias ,  Meir Shinitzky

IPC: A61K039/00 ,  A61K035/78

CPC classification number: A61K38/1709 ,  A61K9/0029 ,  A61K39/0008 ,  A61K39/39 ,  A61K2039/55566 ,  A61K2039/57 ,  C07K14/4713 ,  C07K16/18

Abstract: The present invention provides pharmaceutical compositions and methods for reducing the incidence or severity of insulin dependent diabetes mellitus, insulitis, null-cell destruction, or latent autoimmune diabetes in adults by administering to a patient a pharmaceutical composition comprising an antigen and a carrier, wherein the antigen is recognized by inflammatory T cells associated with the pathogenesis of the disease and the carrier is a metabolizable lipid emulsion. The composition induces a TH1nullTH2 shift in the cytokines produced by said T cells and it is administered in an amount, which is therapeutically effective to reduce the symptoms of the disease.

Abstract translation: 本发明提供了通过向患者施用包含抗原和载体的药物组合物来降低成人胰岛素依赖性糖尿病，胰岛炎，β-细胞破坏或潜伏性自身免疫性糖尿病的发病率或严重程度的药物组合物和方法，其中 抗原被与疾病发病相关的炎性T细胞识别，载体是可代谢的脂质乳剂。 所述组合物诱导由所述T细胞产生的细胞因子中的TH1-> TH2位移，并且其用量以治疗方式有效减少疾病症状。

公开(公告)号：US20020072493A1

公开(公告)日：2002-06-13

申请号：US09893348

申请日：2001-06-28

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Michal Eisenbach-Schwartz ,  Ehud Hauben ,  Irun R. Cohen ,  Pierre Beserman ,  Alon Mosonego ,  Gila Moalem

IPC: A61K038/17

CPC classification number: A61K38/1709 ,  A61K39/00 ,  A61K39/0007 ,  A61K48/00 ,  A61K2039/5158 ,  C07K14/47 ,  C07K14/705

Abstract: Compositions and methods to promote nerve regeneration or to confer neuroprotection and prevent or inhibit neuronal degeneration within the nervous system, eiteher the central nervous system or the peripheral nervous system, are provided. Treatment involves administering NS-specific activated T cells, or an NS-specific antigen or analog thereof, a peptide derived therefrom or an analog or derivative of said peptide, or a nucleotide sequence encoding said antigen or peptide, or any combination thereof.

Abstract translation: 提供了促进神经再生或赋予神经保护作用并预防或抑制神经系统内神经元变性，中枢神经系统或周围神经系统的组合物和方法。 治疗涉及施用NS-特异性活化T细胞或NS-特异性抗原或其类似物，从其衍生的肽或所述肽的类似物或衍生物，或编码所述抗原或肽的核苷酸序列或其任何组合。